JP Morgan reduced its stake in INNOVENT BIO (01801) by approximately 15,536,100 shares, with an average price of around HK$43.05 per share.
On September 11, Xiaomi reduced its holdings in Sino Biopharmaceutical (01801) by 15,536,147 shares, with a price of HK$43.0477 per share, totaling approximately HK$669 million.
According to the latest data from the Hong Kong Stock Exchange, on September 11, JP Morgan reduced its holdings of INNOVENT BIO (01801) by 15,536,147 shares, at a price of 43.0477 Hong Kong dollars per share, for a total amount of approximately 669 million Hong Kong dollars. After the reduction, the latest number of shares held is approximately 87,805,600 shares, with a latest shareholding percentage of 5.38%.
Related Articles
Infotmic Co., Ltd. shareholder Orient intends to reduce its shareholding by no more than 3%.
US Stock Market Move | Palantir (PLTR.US) fell more than 6.7% in response to its impressive Q3 financial report, but the market is concerned that its valuation is too high.
US Stock Market Move | Royal Philips N.V. Sponsored ADR (PHG.US) rises 3% in Q3, adjusted EBITA exceeds expectations.
Infotmic Co., Ltd. shareholder Orient intends to reduce its shareholding by no more than 3%.
US Stock Market Move | Palantir (PLTR.US) fell more than 6.7% in response to its impressive Q3 financial report, but the market is concerned that its valuation is too high.
US Stock Market Move | Royal Philips N.V. Sponsored ADR (PHG.US) rises 3% in Q3, adjusted EBITA exceeds expectations.
RECOMMEND
World’s largest oil company Aramco posts higher Q3 net profit after lifting output
04/11/2025
HSBC, General Atlantic CEOs flag AI capex-revenue mismatch, ‘irrational exuberance’
04/11/2025
Pfizer Files Second Lawsuit Against Novo Nordisk and Metsera Amid Intensifying Bidding Battle Over Obesity Biotech
04/11/2025
